Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs

Biochemical Pharmacology

Volumn 54, Issue 8, 1997, Pages 863-870

  Lainé Cessac, Pascale ^a   Cailleux, Annie ^a   Allain, Pierre ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Drug interactions; Enzymatic inhibition; Pyridoxal; Pyridoxal kinase; Pyridoxal 5' phosphate; Vitamin B6

Indexed keywords

ALLOPURINOL; ALMITRINE; AMANTADINE; AMINEPTINE; CARBAMAZEPINE; CEFOTAXIME; CHLOROQUINE; CISPLATIN; COLCHICINE; CYCLOSERINE; DESIPRAMINE; DIDANOSINE; DOPAMINE; ETHAMBUTOL; FLECAINIDE; FLUCYTOSINE; GABAPENTIN; IMIPRAMINE; ISONIAZID; LEVODOPA; MUZOLIMINE; PENICILLAMINE; PROGABIDE; PYRIDOXAL; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAL KINASE; PYRIDOXAMINE; THEOPHYLLINE; THIAMPHENICOL; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

DRUG INTERACTIONS; ENZYME INHIBITORS; ERYTHROCYTES; GAMMA-AMINOBUTYRIC ACID; HUMANS; KINETICS; MUZOLIMINE; PYRIDOXAL; PYRIDOXAL KINASE; SPECTROPHOTOMETRY, ULTRAVIOLET; THIAMPHENICOL;

EID: 0343907303     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00252-9     Document Type: Article

References (39)

1. Kark JA, Haut MJ, McQuilkin CT and Gibson TP, Enzymatic basis for low pyridoxal-5-phosphate levels in patients on isoniazid therapy. Blood 44: 911, 1974.
2. 6 status and elevated pypridoxal kinase levels induced by theophylline therapy in humans. J Nutr 120: 1352-1359, 1990.
3. 6 deficiency caused by noncompetitive inhibition of pyridoxal kinase. J Lab Clin Med 113: 15-22, 1989.
4. 6 effect of D-penicillamine. Ann NY Acad Sci 166: 57-60, 1969.
5. 6 status. Clin Chim Acta 49: 195-199, 1973.
6. Keniston RC and Weir MR, Aminophylline and gentamicin-2. Am J Clin Nutr 43: 636-637, 1986.
7. 6 levels due to gentamicin. Vet Hum Toxicol 32: 235-238, 1990.
8. 6 function in the rat. Biochem Pharmacol 29: 3097-3102, 1980.
9. 6 antagonist) on pyridoxal enzymes. J Biochem 74: 587-592, 1973.
10. 6 interrelationships in the rat. Can J Biochem Physiol 41: 1215-1222, 1963.
11. Asakura T, Takahashi N, Hirakawa T, Ohkawa K and Hibi N, Regulation of pyridoxal-5′-phosphate level by biogenic amines in mouse brain. Neurochem Res 21: 47-50, 1996.
12. 6 levels due to dopamine. Vet Hum Toxicol 33: 118-121, 1991.
13. 6 levels due to theophylline. Ann Allergy 65: 59-62, 1990.
14. Desta Z and Steingruber M, Pharmacodynamic interactions between isoniazed and theophylline in mice and rats, and the influence of pyridoxine. Pharmazie 47: 525-528, 1992.
15. Smetana S, Khalef S, Kopolovic G, Bar-Khayim Y, Birk Y and Kacew S, Effect of interaction between gentamicin and pyridoxal-5-phosphate on functional and metabolic parameters in kidneys of female Sprague-Dawley rats. Renal Fail 14: 147-153, 1992.
16. Keniston RC, Cabellon S Jr, and Yarbrough KS, Pyridoxal 5′-phosphate as an antidote for cyanide, spermine, gentamicin, and dopamine toxicity: an in vivo rat study. Toxicol Appl Pharmacol 88: 433-441, 1987.
17. Cohen AC, Pyridoxine in the prevention and treatment of convulsions and neurotoxicity due to cycloserine. Ann NY Acad Sci 166: 346-349, 1969.
18. Keniston RC, Polyamine-pyridoxal 5′-phosphate interaction: effects of pH and phosphate concentration in Schiff's base formation. Physiol Chem Phys 11: 465-470, 1979.
19. Braunstein AE, Pyridoxal phosphate. In: The Enzymes, 2. Eds. Boyer PD, Lardy H and Myrback K, p. 113-184. Academic Press, New York, 1960.
20. Ubbink JB, Bissbort S, Vermaak WJH and Delport R, Inhibition of pyridoxal kinase by methylxanthines. Enzyme 43: 72-79, 1990.
21. McCormick DB, Gregory ME and Snell EE, Pyridoxal phosphokinases: I. assay, distribution, purification and properties. J Biol Chem 236: 2076-2084, 1961.
22. Solomon LR and Hillman RS, Pyridoxal kinase activity in human erythrocytes and leukocytes: assay and properties. Biochem Med 16: 223-233, 1976.
23. + on the catalytic activity of human erythrocyte pyridoxal kinase. Enzyme & Protein 49: 291-304, 1996.
24. Churchich JE and Wu C, Nucleoside phosphorothioates as probes of the nucleotide binding site of brain pyridoxal kinase. J Biol Chem 257: 12136-12140, 1982.
25. 6. In: Vitamins. Ed. Friedrich W, pp. 541-618. W. de Gruyter, New York, 1988.
26. 6 metabolism. J Chromatogr 431: 406-412, 1988.
27. 6 nutritional status. J Chromatogr 342: 277-284, 1985.
28. Reynolds RD and Natta CL, Depressed plasma pyridoxal phosphate concentrations in adult asthmatics. Am J Clin Nutr 41: 684-688, 1985.
29. 6 nutritional status in asthma: the effect of theophylline therapy on plasma pyridoxal-5′-phosphate and pyridoxal levels. Int J Vitam Nutr Res 58: 67-72, 1988.
30. 3H-diazepam to the benzodiazepine receptor. Eur J Pharmacol 52: 129-132, 1978.
31. A receptors. Neuropharmacology 21: 391-395, 1982.
32. Decourt JP, Mura P, Papet Y, Piriou A and Reiss D, Simultaneous determination of progabide and its acid metabolite by reversed-phase high-performance liquid chromatography. J Chromatogr 527: 214-219, 1990.
33. Lane RJM and Routledge PA, Drug-induced neurological disorders. Drugs 26: 124-147, 1983.
34. McCormick DB and Snell EE, Pyridoxal phosphokinases: II. effects of inhibitors. J Biol Chem 236: 2085-2088, 1961.
35. Roze U and Strominger JL, The non-enzymatic reaction between D-cycloserine and pyridoxal phosphate. Fed Proc 22: 423, 1963.
36. Manten A, Other antibiotic drugs. In: Side effects of drug annual 1. Ed. Dukes MNG, p. 206-216. Excerpta medica, Amsterdam, 1977.
37. Roe DA, Antivitamins. In: Drug-induced nutritional deficiences. Ed. Roe DA, pp. 154-186. The Avi Publishing Company, Westport, 1976.
38. Rothschild B, Pyridoxine deficiency. Arch Intern Med 142: 840, 1982.
39. Daul A, Graben N and Bock KD, Neuromyoloenzephalopathie nach hochdosierter muzolimin-therapie bei dialysepatienten. Münch Med Wochenschr 129: 542-543, 1987.